Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age: ≥20 years old
Sex: Not specified
Patients with colon/rectal cancer who first underwent FOLFOX, XELOX or SOX regimen including oxaliplatin at ≥85 mg/m2 (naive patient), or those who had already started chemotherapy and had nausea of Grade 2 or higher in the last course or an earlier course (non-naive patient).
Stage: not specified (neoadjuvant/adjuvant chemotherapy, advanced or recurrent type are allowed)
Combination of molecular targeted therapy: allowable
Written informed consent for participation in the study.
You may not be if
Severe liver or kidney disease
Nausea/vomiting within 24 hr prior to chemotherapy.
Treatment with antiemetics within 24 hr prior to chemotherapy.
Presence of factors causing nausea/vomiting other than chemotherapy (e.g. brain tumor, gastrointestinal obstruction, active peptic ulcer disease, brain metastasis)
Presence of a disease precluding 3-day administration of dexamethasone (e.g. uncontrollable diabetes)
Pregnant or lactating women, women who plan to become pregnant.
Current treatment with pimozide.
Any patient judged to be inappropriate for the study by the investigator.
Clareo Health | Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
